Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis

The concept of ‘no evidence of disease activity’ (NEDA) has been proposed as a surrogate marker for treatment response in relapsing-remittent multiple sclerosis (MS). However, there is no agreement regarding its prognostic value, nor about the starting time for evaluation of drug effectiveness. Aim of this stu dy was to investigate if the status preservation of two-year NEDA, ‘minimal evidence of disease activity’ (MEDA) and six-month delayed NEDA (6md-NEDA, with a “rebaseline” six months after the treatment start) predicts the achievement of long-term disability outcomes (EDSS score ≥ 4.0 o r 6.0, 3-month confirmed disability progression (CDP) or conversion to secondary progressive MS) after five and seven years of disease.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Source Type: research